This week at the Intel Devleoper Forum, Intel announced a collaboration with Knight Cancer Institute at Oregon Health & Science University called the Collaborative Cancer Cloud that uses analytics to advance cancer care via genomics analysis and targeted treatment plans. The precision medicine analytics platform allows institutions to securely share patient genomic, imaging and clinical data for potentially lifesaving discoveries. It will also enable large amounts of data from sites all around the world to be analyzed in a distributed way, while preserving the privacy and security of that patient data at each site.
“Precision medicine – taking into account individual differences in people’s genes, environments, and lifestyles – is one of the biggest of the big data problems and is on the cusp of a remarkable transformation in medicine. We view genomics as the first wave of precision medicine, and we’re working with our partners to drive adoption of genomic sequencers, genomic appliances, and cloud-based genomic analytics. With the Collaborative Cancer Cloud, we are combining next generation Intel technologies and bio-science advancements to enable solutions that make it easier, faster, and more affordable for developers, researchers, and clinicians to understand any disease that has a genetic component, starting with Cancer, said Eric Dishman, Intel’s general manager of of Health & Life Sciences in the official announcement.
Intel is expecting to open up the federated, secure Collaborative Cancer Cloud network to additional institutions in 2016 to accelerate the precision treatment options for clinicians to share with their patients. Intel also hopes to advance personalized research in other diseases that are known to have a genetic component, including Alzheimer’s, diabetes, autism, and more.
The end result is to empower researchers and clinicians with the ability to deliver personalized cancer treatments based on their genome within 24 hours by 2020.
